GlobeNewsWire
08 Nov 2025, 22:13 UTC · 47w ago
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
Verdict
Headline takes no side. We score NTLA +1.00 — strongly bullish.
- Expected · NTLA
+1.00strongly bullish
−1 bearish0bullish +1More positive than 98% of ticker scores this week





